Why the study?
Case reports and case series suggested an association between selective serotonin reuptake inhibitors and acute pancreatitis, but results from systematic studies were inconsistent.
Does the use of selective serotonin reuptake inhibitors increase the risk of acute pancreatitis?
Does the use of selective serotonin reuptake inhibitors increase the risk of acute pancreatitis?
A meta-analysis found no statistically significant association between SSRI use and the risk of acute pancreatitis, though a potential risk cannot be entirely excluded.
BACKGROUND/OBJECTIVE: Some case series and case report have shown the association between the risk of acute pancreatitis and use of selective serotonin reuptake inhibitors. The results of systematic studies were not consistent. METHODS: A meta-analysis was performed to investigate the risk of acute pancreatitis associated with use of selective serotonin reuptake inhibitors. RESULTS: There was no statistical association between the risk of acute pancreatitis and selective serotonin reuptake inhibitors use (odds ratio: 1.19, 95% confidence interval: 0.93-1.51). CONCLUSIONS: Despite reaching no statistical significance, the possibility of the association between the risk of acute pancreatitis and selective serotonin reuptake inhibitors use cannot be totally excluded.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: